Paul A. Volberding, MD

Center Co-Director and Principal Investigator
Professor, UCSF Department of Medicine
Director, UCSF AIDS Research Institute
Director of Research, UCSF Global Health Sciences

CFAR Leadership Positions

Internal Advisory Board

CFAR Mentor

Core Management Committee

CFAR Mentees

Publications

  1. El-Sadr WM, Morrison JS, Quinn T, Volberding P. A chronicle of hope and promise: the world as it was, as it is, and as it can be. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S49-50. http://www.ncbi.nlm.nih.gov/pubmed/22797739
  2. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2012 Jul 25; 308(4):387-402. http://www.ncbi.nlm.nih.gov/pubmed/22820792
  3. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul 1; 60 Suppl 1:S1-18. http://www.ncbi.nlm.nih.gov/pubmed/22688010
  4. Brown B, Henry K, Volberding P. A clinical view: a trio of HIV specialists offer their take on HIV--then, now, and in the future. Interview by Heidi M Nass. Posit Aware. 2012; 24(4):2-5. http://www.ncbi.nlm.nih.gov/pubmed/23094300
  5. Martin J, Volberding P. HIV and premature aging: A field still in its infancy. Ann Intern Med. 2010 Oct 5; 153(7):477-9. http://www.ncbi.nlm.nih.gov/pubmed/20921548
  6. Dykes C, Mukherjee AL, Bosch RJ, Connick E, Volberding PA, Demeter LM. Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):132-4. http://www.ncbi.nlm.nih.gov/pubmed/20733405
  7. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21; 304(3):321-33. http://www.ncbi.nlm.nih.gov/pubmed/20639566
  8. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49-62. http://www.ncbi.nlm.nih.gov/pubmed/20609987
  9. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010 Sep; 78(5):478-85. http://www.ncbi.nlm.nih.gov/pubmed/20520594
  10. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010 Feb 9; 121(5):651-8. http://www.ncbi.nlm.nih.gov/pubmed/20100969
  11. Linzer M, Warde C, Alexander RW, Demarco DM, Haupt A, Hicks L, Kutner J, Mangione CM, Mechaber H, Rentz M, Riley J, Schuster B, Solomon GD, Volberding P, Ibrahim T. Part-time careers in academic internal medicine: a report from the association of specialty professors part-time careers task force on behalf of the alliance for academic internal medicine. Acad Med. 2009 Oct; 84(10):1395-400. http://www.ncbi.nlm.nih.gov/pubmed/19881429
  12. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009 Sep 24; 23(15):1987-95. http://www.ncbi.nlm.nih.gov/pubmed/19696651
  13. Volberding P. Cohorts, trials, and evidence: expanding our confidence in guidelines for antiretroviral resistance testing. Ann Intern Med. 2009 Jul 21; 151(2):135-6. http://www.ncbi.nlm.nih.gov/pubmed/19620166
  14. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008 Aug 6; 300(5):555-70. http://www.ncbi.nlm.nih.gov/pubmed/18677028
  15. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007 Dec 15; 45(12):1633-9. http://www.ncbi.nlm.nih.gov/pubmed/18190326
  16. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol. 2007 Nov; 18(11):2968-74. http://www.ncbi.nlm.nih.gov/pubmed/17942954
  17. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007 Dec; 72(11):1380-7. http://www.ncbi.nlm.nih.gov/pubmed/17805235
  18. Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, Volberding PA. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007 May 15; 44(10):1375-83. http://www.ncbi.nlm.nih.gov/pubmed/17443478
  19. Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr. 2007 Jan 1; 44(1):20-9. http://www.ncbi.nlm.nih.gov/pubmed/17091020
  20. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006 Aug 16; 296(7):827-43. http://www.ncbi.nlm.nih.gov/pubmed/16905788
  21. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006 Aug-Sep; 14(3):827-43. http://www.ncbi.nlm.nih.gov/pubmed/17016878
  22. Volberding PA. The New York case: lessons being learned. Ann Intern Med. 2005 May 17; 142(10):866-8. http://www.ncbi.nlm.nih.gov/pubmed/15845950
  23. Behler C, Shade S, Gregory K, Abrams D, Volberding P. Anemia and HIV in the antiretroviral era: potential significance of testosterone. AIDS Res Hum Retroviruses. 2005 Mar; 21(3):200-6. http://www.ncbi.nlm.nih.gov/pubmed/15795525
  24. Michaels MG, Kaufman C, Volberding PA, Gupta P, Switzer WM, Heneine W, Sandstrom P, Kaplan L, Swift P, Damon L, Ildstad ST. Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. Transplantation. 2004 Dec 15; 78(11):1582-9. http://www.ncbi.nlm.nih.gov/pubmed/15591945
  25. Henry DH, Volberding PA, Leitz G. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future. J Acquir Immune Defic Syndr. 2004 Oct 1; 37(2):1221-7. http://www.ncbi.nlm.nih.gov/pubmed/15385728
  26. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29; 351(5):451-9. http://www.ncbi.nlm.nih.gov/pubmed/15282352
  27. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14; 292(2):251-65. http://www.ncbi.nlm.nih.gov/pubmed/15249575
  28. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004 May 15; 38(10):1454-63. http://www.ncbi.nlm.nih.gov/pubmed/15156485
  29. Volberding PA. Initiating HIV therapy. Timing is critical, controversial. Postgrad Med. 2004 Feb; 115(2):15-8, 21, 24-6. http://www.ncbi.nlm.nih.gov/pubmed/15000057
  30. Volberding PA. Opportunities and options for treatment research in resource-constrained settings. Clin Infect Dis. 2003 Jul 1; 37(Suppl 1):S1-3. http://www.ncbi.nlm.nih.gov/pubmed/12822126
  31. Volberding PA. HIV therapy in 2003: consensus and controversy. AIDS. 2003 Apr; 17 Suppl 1:S4-11. http://www.ncbi.nlm.nih.gov/pubmed/12870525
  32. Volberding PA, Murphy RL, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie PF, Di Lorenzo G, Fantoni M, Filiced G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Stein JH, Torre D, Vittecoq D. The pavia consensus statement. AIDS. 2003 Apr; 17 Suppl 1:S170-9. http://www.ncbi.nlm.nih.gov/pubmed/12870544
  33. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003 Mar 28; 17(5):691-8. http://www.ncbi.nlm.nih.gov/pubmed/12646792
  34. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. Hematology Am Soc Hematol Educ Program. 2003; 294-313. http://www.ncbi.nlm.nih.gov/pubmed/14633787
  35. Blower S, Volberding P. What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis. 2002 Dec; 15(6):609-14. http://www.ncbi.nlm.nih.gov/pubmed/12821838
  36. Volberding P. Adherence, resistance, and timing: current issues in the use of new therapies. AIDS Read. 2002 Aug; 12(8):349-50, 356-7, 368. http://www.ncbi.nlm.nih.gov/pubmed/12229892
  37. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002 Jul 10; 288(2):222-35. http://www.ncbi.nlm.nih.gov/pubmed/12095387
  38. Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? JAMA. 2002 Jul 10; 288(2):241-3. http://www.ncbi.nlm.nih.gov/pubmed/12095390
  39. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002 Jul 1; 18(10):685-93. http://www.ncbi.nlm.nih.gov/pubmed/12167274
  40. Volberding P, Sullivan P. Introduction: the importance of identifying and treating complications of human immunodeficiency virus disease. J Infect Dis. 2002 May 15; 185 Suppl 2:S103-4. http://www.ncbi.nlm.nih.gov/pubmed/12001029
  41. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis. 2002 May 15; 185 Suppl 2:S110-4. http://www.ncbi.nlm.nih.gov/pubmed/12001031
  42. Volberding PA. Who cares for AIDS? J Gen Intern Med. 2002 Jan; 17(1):82-3. http://www.ncbi.nlm.nih.gov/pubmed/11903780
  43. Boswell SL, Hecht FM, Powderly WG, Soloway B, Volberding PA. HIV expertise: a roundtable. AIDS Clin Care. 2001 Sep; 13(9):79-81, 84-5. http://www.ncbi.nlm.nih.gov/pubmed/11547599
  44. Gerbert B, Moe JC, Saag MS, Benson CA, Jacobsen DM, Feraios A, Hill ME, Bronstone A, Caspers N, Volberding PA. Toward a definition of HIV expertise: a survey of experienced HIV physicians. AIDS Patient Care STDS. 2001 Jun; 15(6):321-30. http://www.ncbi.nlm.nih.gov/pubmed/11445014
  45. Volberding P, Lange J. International perspectives on antiretroviral resistance. Introduction. J Acquir Immune Defic Syndr. 2001 Mar 1; 26 Suppl 1:S1-2. http://www.ncbi.nlm.nih.gov/pubmed/11265002
  46. Volberding P. Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther. 2000 Sep; 22(9):1004-1020; discussion 1003. http://www.ncbi.nlm.nih.gov/pubmed/11048901
  47. Volberding P. Looking behind: time for anal cancer screening. Am J Med. 2000 Jun 1; 108(8):674-5. http://www.ncbi.nlm.nih.gov/pubmed/10856420
  48. Volberding P. When and where to start: guidelines for the initiation of antiretroviral therapy. AIDS Read. 2000 Mar; 10(3):150-5; discussion 171-4. http://www.ncbi.nlm.nih.gov/pubmed/10758014
  49. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000 Jan 19; 283(3):381-90. http://www.ncbi.nlm.nih.gov/pubmed/10647802
  50. Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS. 1999 Sep 10; 13(13):1771-8. http://www.ncbi.nlm.nih.gov/pubmed/10509580
  51. Volberding PA. Advances in the medical management of patients with HIV-1 infection: an overview. AIDS. 1999 Sep; 13 Suppl 1:S1-9. http://www.ncbi.nlm.nih.gov/pubmed/10546780
  52. Gerbert B, Herzig K, Volberding P, Stansell J. Perceptions of health care professionals and patients about the risk of HIV transmission through oral sex: a qualitative study. Patient Educ Couns. 1999 Sep; 38(1):49-60. http://www.ncbi.nlm.nih.gov/pubmed/14528571
  53. Gerbert B, Brown B, Volberding P, Cooke M, Caspers N, Love C, Bronstone A. Physicians' transmission prevention assessment and counseling practices with their HIV positive patients. AIDS Educ Prev. 1999 Aug; 11(4):307-20. http://www.ncbi.nlm.nih.gov/pubmed/10494355
  54. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. http://www.ncbi.nlm.nih.gov/pubmed/10228057
  55. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998 Jul 1; 280(1):78-86. http://www.ncbi.nlm.nih.gov/pubmed/9660368
  56. Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998 May 6; 279(17):1343-4. http://www.ncbi.nlm.nih.gov/pubmed/9582033
  57. Volberding PA. An aggressive approach to HIV antiretroviral therapy. Hosp Pract (Minneap). 1998 Jan 15; 33(1):81-4, 87-90, 95-6 passim. http://www.ncbi.nlm.nih.gov/pubmed/9464233
  58. Volberding PA. HIV/AIDS. Protease inhibitors vindicated. Lancet. 1997 Dec 20-27; 350 Suppl 3:SIII10. http://www.ncbi.nlm.nih.gov/pubmed/9465186
  59. Gerbert B, Herzig K, Volberding P. Counseling patients about HIV risk from oral sex. J Gen Intern Med. 1997 Nov; 12(11):698-704. http://www.ncbi.nlm.nih.gov/pubmed/9383138
  60. Ioannidis JP, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1; 16(1):22-30. http://www.ncbi.nlm.nih.gov/pubmed/9377121
  61. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25; 277(24):1962-9. http://www.ncbi.nlm.nih.gov/pubmed/9200638
  62. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev. 1997-1998; 145-85. http://www.ncbi.nlm.nih.gov/pubmed/9305448
  63. Volberding PA. Medicine and HIV. Interview by David Frankel. Lancet. 1996 Oct 12; 348(9033):1007-8. http://www.ncbi.nlm.nih.gov/pubmed/8855865
  64. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Sáag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10; 276(2):146-54. http://www.ncbi.nlm.nih.gov/pubmed/8656507
  65. Volberding PA. Age as a predictor of progression in HIV infection. Lancet. 1996 Jun 8; 347(9015):1569-70. http://www.ncbi.nlm.nih.gov/pubmed/8667860
  66. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. HIV viral load markers in clinical practice. Nat Med. 1996 Jun; 2(6):625-9. http://www.ncbi.nlm.nih.gov/pubmed/8640545
  67. Volberding PA. Improving the outcomes of care for patients with human immunodeficiency virus infection. N Engl J Med. 1996 Mar 14; 334(11):729-31. http://www.ncbi.nlm.nih.gov/pubmed/8594437
  68. Volberding PA. HIV quantification: clinical applications. Lancet. 1996 Jan 13; 347(8994):71-3. http://www.ncbi.nlm.nih.gov/pubmed/8538341
  69. Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P. Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1; 11(1):45-52. http://www.ncbi.nlm.nih.gov/pubmed/8528732
  70. Volberding PA. Controversies in initiating anti-retroviral therapy and in the use of combination therapies. Adv Exp Med Biol. 1996; 394:333-43. http://www.ncbi.nlm.nih.gov/pubmed/8815699
  71. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996 Jan; 36(1):55-63. http://www.ncbi.nlm.nih.gov/pubmed/8932544
  72. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med. 1995 Aug 17; 333(7):401-7. http://www.ncbi.nlm.nih.gov/pubmed/7616988
  73. Deeks S, Volberding P. An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. Hosp Pract (Minneap). 1995 Aug; 30 Suppl 1:23-31. http://www.ncbi.nlm.nih.gov/pubmed/7635914
  74. Kaplan LD, Shiramizu B, Herndier B, Hahn J, Meeker TC, Ng V, Volberding PA, McGrath MS. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome. Blood. 1995 Apr 1; 85(7):1727-35. http://www.ncbi.nlm.nih.gov/pubmed/7535586
  75. Volberding P. The need for additional options in the treatment of human immunodeficiency virus infection. J Infect Dis. 1995 Mar; 171 Suppl 2:S150-4. http://www.ncbi.nlm.nih.gov/pubmed/7861020
  76. Volberding P. The value of the CD4+ count of 500 cells/microliters. Drugs. 1995; 49 Suppl 1:4-8; discussion 38-40. http://www.ncbi.nlm.nih.gov/pubmed/7614901
  77. Fogelman I, Lim L, Bassett R, Volberding P, Fischl MA, Stanley K, Cotton DJ. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG). J Acquir Immune Defic Syndr. 1994 Oct; 7(10):1057-63. http://www.ncbi.nlm.nih.gov/pubmed/8083823
  78. Little JW, Melnick SL, Rhame FS, Balfour HH, Decher L, Rhodus NL, Merry JW, Walker PO, Miller CE, Volberding P. Prevalence of oral lesions in symptomatic and asymptomatic HIV patients. Gen Dent. 1994 Sep-Oct; 42(5):446-50. http://www.ncbi.nlm.nih.gov/pubmed/7489878
  79. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Phair JP, Mitsuyasu RT, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994 Aug 10; 272(6):437-42. http://www.ncbi.nlm.nih.gov/pubmed/7913730
  80. Hardy LM, Haynes BF, Volberding PA. From the Institute of Medicine. JAMA. 1994 Aug 10; 272(6):423. http://www.ncbi.nlm.nih.gov/pubmed/8040965
  81. Volberding PA. Intermittent therapy. J Acquir Immune Defic Syndr. 1994 May; 7(5):454-6. http://www.ncbi.nlm.nih.gov/pubmed/8158538
  82. Macher A, Goosby E, Barker L, Volberding P, Goldschmidt R, Balano KB, Williams A, Hoenig L, Gould B, Daniels E. Educating primary care providers about HIV disease: multidisciplinary interactive mechanisms. Public Health Rep. 1994 May-Jun; 109(3):305-10. http://www.ncbi.nlm.nih.gov/pubmed/8190853
  83. Volberding PA. Treatment dilemmas in HIV infection. Hosp Pract (Off Ed). 1994 Apr 15; 29(4):49-54, 59-60. http://www.ncbi.nlm.nih.gov/pubmed/7908297
  84. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis. 1994 Apr; 169(4):713-21. http://www.ncbi.nlm.nih.gov/pubmed/8133085
  85. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994 Mar 17; 330(11):738-43. http://www.ncbi.nlm.nih.gov/pubmed/7906386
  86. Volberding PA. HIV, HTLV-I, and CD4+ lymphocytes. Troubles in the relationship. JAMA. 1994 Feb 2; 271(5):392-3. http://www.ncbi.nlm.nih.gov/pubmed/7904318
  87. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994 Jan; 169(1):28-36. http://www.ncbi.nlm.nih.gov/pubmed/7903975
  88. Sale M, Sheiner LB, Volberding P, Blaschke TF. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther. 1993 Nov; 54(5):556-66. http://www.ncbi.nlm.nih.gov/pubmed/7900949
  89. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993 Oct 15; 119(8):786-93. http://www.ncbi.nlm.nih.gov/pubmed/8379600
  90. Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993 May 1; 118(9):674-80. http://www.ncbi.nlm.nih.gov/pubmed/8096373
  91. Fischl MA, Krown SE, O'Boyle KP, Mitsuyasu R, Miles S, Wernz JC, Volberding PA, Kahn J, Groopman JE, Feinberg J, et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1993 Mar; 6(3):259-64. http://www.ncbi.nlm.nih.gov/pubmed/8450401
  92. Koch MA, Volberding PA, Lagakos SW, Booth DK, Pettinelli C, Myers MW. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group. Arch Intern Med. 1992 Nov; 152(11):2286-92. http://www.ncbi.nlm.nih.gov/pubmed/1359846
  93. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992 Aug 27; 327(9):581-7. http://www.ncbi.nlm.nih.gov/pubmed/1353607
  94. Kahn JO, Stites DP, Scillian J, Murcar N, Stryker R, Volberding PA, Naylor PH, Goldstein AL, Sarin PS, Simmon VF, et al. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. AIDS Res Hum Retroviruses. 1992 Aug; 8(8):1321-5. http://www.ncbi.nlm.nih.gov/pubmed/1466950
  95. Volberding P. Optimal time to initiate anti-HIV therapy: clinical decisions without definitive data. Infect Agents Dis. 1992 Jun; 1(3):163-6. http://www.ncbi.nlm.nih.gov/pubmed/1365541
  96. Volberding PA. Epidemiology and the human immunodeficiency virus. Clinical effects of intravenous drug misuse. JAMA. 1992 Mar 25; 267(12):1666-7. http://www.ncbi.nlm.nih.gov/pubmed/1542178
  97. Safrin S, Volberding P. Management of the complications of human immunodeficiency virus infection. Adv Intern Med. 1992; 37:133-52. http://www.ncbi.nlm.nih.gov/pubmed/1557994
  98. Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS. 1992 Jan; 6(1):127. http://www.ncbi.nlm.nih.gov/pubmed/1311935
  99. Gatti G, Kahn JO, Lifson J, Williams R, Turin L, Volberding PA, Gambertoglio JG. Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Antimicrob Agents Chemother. 1991 Dec; 35(12):2531-7. http://www.ncbi.nlm.nih.gov/pubmed/1810186
  100. Hodges TL, Kahn JO, Kaplan LD, Groopman JE, Volberding PA, Amman AJ, Arri CJ, Bouvier LM, Mordenti J, Izu AE, et al. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother. 1991 Dec; 35(12):2580-6. http://www.ncbi.nlm.nih.gov/pubmed/1810192
  101. Lagakos S, Fischl MA, Stein DS, Lim L, Volberding P. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA. 1991 Nov 20; 266(19):2709-12. http://www.ncbi.nlm.nih.gov/pubmed/1942422
  102. Kahn J, Northfelt D, Volberding P. Chemotherapy for AIDS-associated Kaposi's sarcoma. Oncology (Williston Park). 1991 Oct; 5(10):57-63; discussion 64, 67. http://www.ncbi.nlm.nih.gov/pubmed/1838275
  103. Drinkard CR, Decher L, Little JW, Rhame FS, Balfour HH, Rhodus NL, Merry JW, Walker PO, Miller CE, Volberding PA, et al. Periodontal status of individuals in early stages of human immunodeficiency virus infection. Community Dent Oral Epidemiol. 1991 Oct; 19(5):281-5. http://www.ncbi.nlm.nih.gov/pubmed/1742994
  104. Volberding P. The management of early human immunodeficiency virus infection. J Thorac Imaging. 1991 Sep; 6(4):6-11. http://www.ncbi.nlm.nih.gov/pubmed/1942200
  105. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991 Jun; 9(6):929-40. http://www.ncbi.nlm.nih.gov/pubmed/2033429
  106. Krogstad DJ, Eveland MR, Lim LL, Volberding PA, Sadler BM. Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019. Antimicrob Agents Chemother. 1991 Jun; 35(6):1160-4. http://www.ncbi.nlm.nih.gov/pubmed/1929258
  107. Northfelt DW, Kahn JO, Volberding PA. Treatment of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am. 1991 Apr; 5(2):297-310. http://www.ncbi.nlm.nih.gov/pubmed/2022595
  108. Evans LM, Itri LM, Campion M, Wyler-Plaut R, Krown SE, Groopman JE, Goldsweig H, Volberding PA, West SB, Mitsuyasu RT, et al. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother (1991). 1991 Feb; 10(1):39-50. http://www.ncbi.nlm.nih.gov/pubmed/1826454
  109. Tappero JW, Berger TG, Kaplan LD, Volberding PA, Kahn JO. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr. 1991; 4(9):839-46. http://www.ncbi.nlm.nih.gov/pubmed/1895204
  110. Hendrix CW, Volberding PA, Chaisson RE. HIV antigen variability in ARC/AIDS. J Acquir Immune Defic Syndr. 1991; 4(9):847-50. http://www.ncbi.nlm.nih.gov/pubmed/1910082
  111. Melnick SL, Hannan P, Decher L, Little JW, Rhame FS, Balfour HH, Volberding P. Increasing CD8+ T lymphocytes predict subsequent development of intraoral lesions among individuals in the early stages of infection by the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1991; 4(12):1199-207. http://www.ncbi.nlm.nih.gov/pubmed/1682473
  112. Cooke M, Libman H, Smith MD, Cooney TG, Hollander H, Makadon HJ, Volberding PA. Controversies in the management of HIV-related illnesses. J Gen Intern Med. 1991 Jan-Feb; 6(1 Suppl):S46-55. http://www.ncbi.nlm.nih.gov/pubmed/2005478
  113. Volberding PA. Recent advances in the medical management of early HIV disease. J Gen Intern Med. 1991 Jan-Feb; 6(1 Suppl):S7-12. http://www.ncbi.nlm.nih.gov/pubmed/2005480
  114. Kahn JO, Kaplan LD, Gambertoglio JG, Bredesen D, Arri CJ, Turin L, Kibort T, Williams RL, Lifson JD, Volberding PA. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS. 1990 Dec; 4(12):1197-204. http://www.ncbi.nlm.nih.gov/pubmed/2088398
  115. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990 Sep 20; 323(12):769-75. http://www.ncbi.nlm.nih.gov/pubmed/1975426
  116. Montgomery H, Adam A, Dollery CT, Weber J, Volberding P, Griffin B, Scaravilli F. Cerebral mass lesions in patients with AIDS. BMJ. 1990 Jul 28; 301(6745):226-8. http://www.ncbi.nlm.nih.gov/pubmed/2203488
  117. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5; 322(14):941-9. http://www.ncbi.nlm.nih.gov/pubmed/1969115
  118. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion. 1990 Feb; 30(2):133-7. http://www.ncbi.nlm.nih.gov/pubmed/2305441
  119. Tirelli U, Micheluz S, Franceschi S, Serraino D, Lazzarin A, Sacco OL, Clumeck N, Volberding P. Attitudes and opinions toward HIV infection of 1,008 participants to the Vth International Conference on AIDS Montreal, 4-9 June 1989. J Acquir Immune Defic Syndr. 1990; 3(7):742. http://www.ncbi.nlm.nih.gov/pubmed/2352128
  120. Volberding PA. Rationale for variations in clinical trial design in different HIV disease stages. J Acquir Immune Defic Syndr. 1990; 3 Suppl 2:S40-4. http://www.ncbi.nlm.nih.gov/pubmed/2231301
  121. Volberding PA, McCutchan JA. The HIV epidemic: medical and social challenges. Biochim Biophys Acta. 1989 Dec 27; 989(3):227-36. http://www.ncbi.nlm.nih.gov/pubmed/2695167
  122. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989 Nov 3; 262(17):2405-10. http://www.ncbi.nlm.nih.gov/pubmed/2677429
  123. Volberding PA. Moving towards a uniform staging for human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1989 Sep; 7(9):1184-5. http://www.ncbi.nlm.nih.gov/pubmed/2769326
  124. Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun; 159(6):1029-36. http://www.ncbi.nlm.nih.gov/pubmed/2566637
  125. Volberding P. Supporting the health care team in caring for patients with AIDS. JAMA. 1989 Feb 3; 261(5):747-8. http://www.ncbi.nlm.nih.gov/pubmed/2911172
  126. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding PA. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA. 1989 Feb 3; 261(5):719-24. http://www.ncbi.nlm.nih.gov/pubmed/2536124
  127. Kaplan LD, Abrams DI, Sherwin SA, Kahn J, Volberding PA. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex. Biotechnol Ther. 1989-1990; 1(3):229-36. http://www.ncbi.nlm.nih.gov/pubmed/2562651
  128. Volberding PA. Kaposi's sarcoma in AIDS. Immunol Ser. 1989; 44:345-58. http://www.ncbi.nlm.nih.gov/pubmed/2489116
  129. Kahn JO, Kaplan LD, Volberding PA, Ziegler JL, Crowe S, Saks SR, Abrams DI. Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial. J Acquir Immune Defic Syndr. 1989; 2(3):217-23. http://www.ncbi.nlm.nih.gov/pubmed/2498507
  130. Volberding PA, Kaplan LD. Treatment of AIDS and its attendant malignancies. Prog Clin Biol Res. 1989; 288:459-70. http://www.ncbi.nlm.nih.gov/pubmed/2654959
  131. Volberding P. HIV infection as a disease: the medical indications for early diagnosis. J Acquir Immune Defic Syndr. 1989; 2(5):421-5. http://www.ncbi.nlm.nih.gov/pubmed/2795447
  132. Wong RJ, Volberding PA. Providing clinical pharmacy services in an AIDS--oncology ambulatory-care clinic. Am J Hosp Pharm. 1988 Nov; 45(11):2351-4. http://www.ncbi.nlm.nih.gov/pubmed/2852473
  133. Chaisson RE, Leuther MD, Allain JP, Nusinoff-Lehrman S, Boone GS, Feigal D, Volberding P. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial. Arch Intern Med. 1988 Oct; 148(10):2151-3. http://www.ncbi.nlm.nih.gov/pubmed/3263098
  134. Volberding P. Zidovudine (AZT): costs and benefits. Br J Hosp Med. 1988 Aug; 40(2):101. http://www.ncbi.nlm.nih.gov/pubmed/3139119
  135. Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis. 1988 Aug; 158(2):489-90. http://www.ncbi.nlm.nih.gov/pubmed/3261316
  136. Volberding PA. Caring for the patient with AIDS. An integrated approach. Infect Dis Clin North Am. 1988 Jun; 2(2):543-50. http://www.ncbi.nlm.nih.gov/pubmed/3204267
  137. Volberding P. Treatment of malignant disease in AIDS patients. AIDS. 1988; 2 Suppl 1:S169-75. http://www.ncbi.nlm.nih.gov/pubmed/3147666
  138. Kaplan LD, Hopewell PC, Jaffe H, Goodman PC, Bottles K, Volberding PA. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988; 1(1):23-30. http://www.ncbi.nlm.nih.gov/pubmed/3265151
  139. Bottles K, McPhaul LW, Volberding P. Fine-needle aspiration biopsy of patients with acquired immunodeficiency syndrome (AIDS): experience in an outpatient clinic. Ann Intern Med. 1988 Jan; 108(1):42-5. http://www.ncbi.nlm.nih.gov/pubmed/3337514
  140. Ammann AJ, Palladino MA, Volberding P, Abrams D, Martin NL, Conant M. Tumor necrosis factors alpha and beta in acquired immunodeficiency syndrome (AIDS) and aids-related complex. J Clin Immunol. 1987 Nov; 7(6):481-5. http://www.ncbi.nlm.nih.gov/pubmed/3693521
  141. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE, Gill P, Volberding PA, Poiesz BJ, et al. Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. JAMA. 1987 Sep 11; 258(10):1347-51. http://www.ncbi.nlm.nih.gov/pubmed/3650339
  142. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):185-91. http://www.ncbi.nlm.nih.gov/pubmed/3299089
  143. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):192-7. http://www.ncbi.nlm.nih.gov/pubmed/3299090
  144. Volberding PA. The role of chemotherapy for epidemic Kaposi's sarcoma. Semin Oncol. 1987 Jun; 14(2 Suppl 3):23-6. http://www.ncbi.nlm.nih.gov/pubmed/2440109
  145. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1987 Jun; 14(2 Suppl 2):43-7. http://www.ncbi.nlm.nih.gov/pubmed/3589704
  146. Kaplan LD, Wolfe PR, Volberding PA, Feorino P, Levy JA, Abrams DI, Kiprov D, Wong R, Kaufman L, Gottlieb MS. Lack of response to suramin in patients with AIDS and AIDS-related complex. Am J Med. 1987 Mar 23; 82(3 Spec No):615-20. http://www.ncbi.nlm.nih.gov/pubmed/3548350
  147. Kaplan LD, Wofsy CB, Volberding PA. Treatment of patients with acquired immunodeficiency syndrome and associated manifestations. JAMA. 1987 Mar 13; 257(10):1367-74. http://www.ncbi.nlm.nih.gov/pubmed/3546745
  148. Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer. 1987 Feb 1; 59(3 Suppl):620-5. http://www.ncbi.nlm.nih.gov/pubmed/3492260
  149. Hardell L, Moss A, Osmond D, Volberding P. Exposure to hair dyes and polychlorinated dibenzo-p-dioxins in AIDS patients with Kaposi sarcoma: an epidemiological investigation. Cancer Detect Prev Suppl. 1987; 1:567-70. http://www.ncbi.nlm.nih.gov/pubmed/3480068
  150. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses. 1987; 3(2):115-24. http://www.ncbi.nlm.nih.gov/pubmed/3113462
  151. Chaisson RE, Allain JP, Leuther M, Volberding PA. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med. 1986 Dec 18; 315(25):1610-1. http://www.ncbi.nlm.nih.gov/pubmed/3466034
  152. Abrams DI, Kaplan LD, McGrath MS, Volberding PA. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions. AIDS Res. 1986 Dec; 2 Suppl 1:S131-40. http://www.ncbi.nlm.nih.gov/pubmed/3828009
  153. Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis. 1986 Nov; 134(5):891-6. http://www.ncbi.nlm.nih.gov/pubmed/3777686
  154. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep. 1986 Sep; 70(9):1121-2. http://www.ncbi.nlm.nih.gov/pubmed/3742492
  155. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):43-7. http://www.ncbi.nlm.nih.gov/pubmed/3532335
  156. Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul; 105(1):37-44. http://www.ncbi.nlm.nih.gov/pubmed/3521428
  157. Volberding PA. Kaposi's sarcoma and the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May; 70(3):665-75. http://www.ncbi.nlm.nih.gov/pubmed/3007893
  158. Abrams DI, Dilley JW, Maxey LM, Volberding PA. Routine care and psychosocial support of the patient with the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May; 70(3):707-20. http://www.ncbi.nlm.nih.gov/pubmed/3959664
  159. Groopman JE, Chen FW, Hope JA, Andrews JM, Swift RL, Benton CV, Sullivan JL, Volberding PA, Sites DP, Landesman S, et al. Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis. 1986 Apr; 153(4):736-42. http://www.ncbi.nlm.nih.gov/pubmed/3005434
  160. Steinbrook R, Lo B, Moulton J, Saika G, Hollander H, Volberding PA. Preferences of homosexual men with AIDS for life-sustaining treatment. N Engl J Med. 1986 Feb 13; 314(7):457-60. http://www.ncbi.nlm.nih.gov/pubmed/3945276
  161. Abrams DI, Kiprov DD, Goedert JJ, Sarngadharan MG, Gallo RC, Volberding PA. Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med. 1986 Jan; 104(1):47-50. http://www.ncbi.nlm.nih.gov/pubmed/3000249
  162. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol. 1985 Dec; 12(4 Suppl 5):2-6. http://www.ncbi.nlm.nih.gov/pubmed/3909416
  163. Volberding PA. The clinical spectrum of the acquired immunodeficiency syndrome: implications for comprehensive patient care. Ann Intern Med. 1985 Nov; 103(5):729-33. http://www.ncbi.nlm.nih.gov/pubmed/4051349
  164. Steinbrook R, Lo B, Tirpack J, Dilley JW, Volberding PA. Ethical dilemmas in caring for patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Nov; 103(5):787-90. http://www.ncbi.nlm.nih.gov/pubmed/4051355
  165. Volberding PA, Abrams DI, Conant M, Kaslow K, Vranizan K, Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Sep; 103(3):335-8. http://www.ncbi.nlm.nih.gov/pubmed/4026082
  166. Kaplan L, Volberding PA. Failure (and danger) of mitozantrone in AIDS-related Kaposi's sarcoma. Lancet. 1985 Aug 17; 2(8451):396. http://www.ncbi.nlm.nih.gov/pubmed/2862556
  167. Kaminsky LS, McHugh T, Stites D, Volberding P, Henle G, Henle W, Levy JA. High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A. 1985 Aug; 82(16):5535-9. http://www.ncbi.nlm.nih.gov/pubmed/2991932
  168. Volberding P, Abrams D. Clinical care and research in AIDS. Hastings Cent Rep. 1985 Aug; 15(4):suppl 16-8. http://www.ncbi.nlm.nih.gov/pubmed/4055346
  169. Moss AR, Bacchetti P, Osmond D, Dritz S, Abrams D, Conant M, Volberding P, Ziegler J. Incidence of the acquired immunodeficiency syndrome in San Francisco, 1980-1983. J Infect Dis. 1985 Jul; 152(1):152-61. http://www.ncbi.nlm.nih.gov/pubmed/3874250
  170. Shannon K, Cowan MJ, Ball E, Abrams D, Volberding P, Ammann AJ. Impaired mononuclear-cell proliferation in patients with the acquired immune deficiency syndrome results from abnormalities of both T lymphocytes and adherent mononuclear cells. J Clin Immunol. 1985 Jul; 5(4):239-45. http://www.ncbi.nlm.nih.gov/pubmed/3876352
  171. Roth RI, Owen RL, Keren DF, Volberding PA. Intestinal infection with Mycobacterium avium in acquired immune deficiency syndrome (AIDS). Histological and clinical comparison with Whipple's disease. Dig Dis Sci. 1985 May; 30(5):497-504. http://www.ncbi.nlm.nih.gov/pubmed/2580679
  172. Abrams DI, Mess T, Volberding PA. Lymphadenopathy: end-point prodrome? Update of a 36-month prospective study. Adv Exp Med Biol. 1985; 187:73-84. http://www.ncbi.nlm.nih.gov/pubmed/2994422
  173. Lie-Injo LE, Volberding P, Golden JA, Herrera AR. Hepatitis B virus (HBV) DNA in leucocytes in acquired immune deficiency syndrome (AIDS). Cytobios. 1985; 44(176):119-28. http://www.ncbi.nlm.nih.gov/pubmed/3004832
  174. Volberding PA. The problem of Kaposi's sarcoma in AIDS. Front Radiat Ther Oncol. 1985; 19:91-8. http://www.ncbi.nlm.nih.gov/pubmed/3884452
  175. Volberding PA, Wofsy CB, Abrams DI. Interferon and interleukin-2 therapy of Kaposi's sarcoma. Adv Exp Med Biol. 1985; 187:151-7. http://www.ncbi.nlm.nih.gov/pubmed/3875980
  176. Abrams DI, Kiprov DD, Volberding PA. Isolated thrombocytopenia in homosexual men--longitudinal follow-up. Adv Exp Med Biol. 1985; 187:117-22. http://www.ncbi.nlm.nih.gov/pubmed/3929576
  177. Dilley JW, Ochitill HN, Perl M, Volberding PA. Findings in psychiatric consultations with patients with acquired immune deficiency syndrome. Am J Psychiatry. 1985 Jan; 142(1):82-6. http://www.ncbi.nlm.nih.gov/pubmed/3966588
  178. Moss AR, Abrams D, Conant M, Volberding P. Incidence of the acquired immunodeficiency syndrome in San Francisco. Front Radiat Ther Oncol. 1985; 19:14-20. http://www.ncbi.nlm.nih.gov/pubmed/3979822
  179. Moss AR, McCallum G, Volberding PA, Bacchetti P, Dritz S. Mortality associated with mode of presentation in the acquired immune deficiency syndrome. J Natl Cancer Inst. 1984 Dec; 73(6):1281-4. http://www.ncbi.nlm.nih.gov/pubmed/6334770
  180. Torti FM, Porzig KJ, Gandara DR, Volberding P, Mitchell E, Meyers FJ, Kohler M, Gribble M. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep. 1984 Dec; 68(12):1509-10. http://www.ncbi.nlm.nih.gov/pubmed/6595059
  181. Hammock BD, Loury DN, Moody DE, Ruebner B, Baselt R, Milam KM, Volberding P, Ketterman A, Talcott R. A methodology for the analysis of the preneoplastic antigen. Carcinogenesis. 1984 Nov; 5(11):1467-73. http://www.ncbi.nlm.nih.gov/pubmed/6488472
  182. Ziegler JL, Volberding PA, Itri LM. Failure of isotretinoin in Kaposi's sarcoma. Lancet. 1984 Sep 15; 2(8403):641. http://www.ncbi.nlm.nih.gov/pubmed/6147674
  183. Ziegler JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, Gill PS, Burkes RL, Meyer PR, Metroka CE, et al. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 30; 311(9):565-70. http://www.ncbi.nlm.nih.gov/pubmed/6611504
  184. Ammann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA. 1984 Mar 16; 251(11):1447-9. http://www.ncbi.nlm.nih.gov/pubmed/6608011
  185. Volberding P. Therapy of Kaposi's sarcoma in AIDS. Semin Oncol. 1984 Mar; 11(1):60-7. http://www.ncbi.nlm.nih.gov/pubmed/6372100
  186. Moon KL, Federle MP, Abrams DI, Volberding P, Lewis BJ. Kaposi sarcoma and lymphadenopathy syndrome: limitations of abdominal CT in acquired immunodeficiency syndrome. Radiology. 1984 Feb; 150(2):479-83. http://www.ncbi.nlm.nih.gov/pubmed/6691105
  187. Groopman JE, Volberding PA. The AIDS epidemic: continental drift. Nature. 1984 Jan 19-25; 307(5948):211-2. http://www.ncbi.nlm.nih.gov/pubmed/6694724
  188. Abrams DI, Chinn EK, Lewis BJ, Volberding PA, Conant MA, Townsend RM. Hematologic manifestations in homosexual men with Kaposi's sarcoma. Am J Clin Pathol. 1984 Jan; 81(1):13-8. http://www.ncbi.nlm.nih.gov/pubmed/6704205
  189. Ziegler JL, Bragg K, Abrams D, Beckstead J, Cogan M, Volberding P, Baer D, Wilkinson L, Rosenbaum E, Grant K, et al. High-grade non-Hodgkin's lymphoma in patients with AIDS. Ann N Y Acad Sci. 1984; 437:412-9. http://www.ncbi.nlm.nih.gov/pubmed/6598309
  190. Volberding P, Valero R, Rothman J, Gee G. Alpha interferon therapy of Kaposi's sarcoma in AIDS. Ann N Y Acad Sci. 1984; 437:439-46. http://www.ncbi.nlm.nih.gov/pubmed/6398652
  191. Abrams DI, Lewis BJ, Volberding PA. Lymphadenopathy: endpoint or prodrome? Update of a 24-month prospective study. Ann N Y Acad Sci. 1984; 437:207-15. http://www.ncbi.nlm.nih.gov/pubmed/6335951
  192. Lozada F, Silverman S, Migliorati CA, Conant MA, Volberding PA. Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): findings in 53 homosexual men with Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol. 1983 Nov; 56(5):491-4. http://www.ncbi.nlm.nih.gov/pubmed/6580594
  193. Rubenstein SA, Jenkin WM, Conant MA, Volberding PA. Disseminated Kaposi's sarcoma in male homosexuals. J Am Podiatry Assoc. 1983 Aug; 73(8):413-7. http://www.ncbi.nlm.nih.gov/pubmed/6619493
  194. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N Engl J Med. 1983 Jun 23; 308(25):1535-6. http://www.ncbi.nlm.nih.gov/pubmed/6222258
  195. Ammann AJ, Abrams D, Conant M, Chudwin D, Cowan M, Volberding P, Lewis B, Casavant C. Acquired immune dysfunction in homosexual men: immunologic profiles. Clin Immunol Immunopathol. 1983 Jun; 27(3):315-25. http://www.ncbi.nlm.nih.gov/pubmed/6223758
  196. Moss AR, Bacchetti P, Gorman M, Dritz S, Conant M, Abrams DI, Volberding P, Ziegler J. AIDS in the "gay" areas of San Francisco. Lancet. 1983 Apr 23; 1(8330):923-4. http://www.ncbi.nlm.nih.gov/pubmed/6132235
  197. Volberding P, Conant MA, Stricker RB, Lewis BJ. Chemotherapy in advanced Kaposi's sarcoma. Implications for current cases in homosexual men. Am J Med. 1983 Apr; 74(4):652-6. http://www.ncbi.nlm.nih.gov/pubmed/6837590
  198. Drew WL, Conant MA, Miner RC, Huang ES, Ziegler JL, Groundwater JR, Gullett JH, Volberding P, Abrams DI, Mintz L. Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet. 1982 Jul 17; 2(8290):125-7. http://www.ncbi.nlm.nih.gov/pubmed/6123839
  199. Conant MA, Volberding P, Fletcher V, Lozada FI, Silverman S. Squamous cell carcinoma in sexual partner of Kaposi sarcoma patient. Lancet. 1982 Jan 30; 1(8266):286. http://www.ncbi.nlm.nih.gov/pubmed/6120304
  200. Volberding PA, Friedman MA, Resser KJ, Phillips TL. Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate. Cancer Chemother Pharmacol. 1982; 9(1):17-21. http://www.ncbi.nlm.nih.gov/pubmed/7139849
  201. Fischbach M, Volberding P, Talal N, Levy J. Genetic analysis of induction of anti-polyadenylic acid antibodies and xenotropic type-C viruses. Clin Exp Immunol. 1981 Jun; 44(3):615-9. http://www.ncbi.nlm.nih.gov/pubmed/6276056
  202. Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Phillips TL. Therapy of hepatocellular cancer with combined intrahepatic arterial chemotherapy and whole liver irradiation. Ann Acad Med Singapore. 1980 Apr; 9(2):260-3. http://www.ncbi.nlm.nih.gov/pubmed/6252817
  203. Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Phillips TL. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1885-8. http://www.ncbi.nlm.nih.gov/pubmed/230895
  204. Moldow CF, Volberding P, McGrath M, Lee JL. Avian tumour virus interactions with chicken fibroblast membranes: partial characterization of initial attachment site activity. J Gen Virol. 1977 Nov; 37(2):385-98. http://www.ncbi.nlm.nih.gov/pubmed/200712

Support CFAR | Contact | Privacy Policy | Photos | Feedback | Subscribe

© Copyright 2013, Regents of the University of California

Our center is supported by a grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases: P30 AI027763